Arecor Ltd , the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™.
Advancing today's therapies to enable healthier lives.
Telephone: +44 (0)1223 426 060
Chesterford Research Park Little Chesterford Saffron Walden
Post Code: CB10 1XL
Country: United Kingdom
Membership Type: Corporate 21-50